Eurofins · 8 hours ago
Cell and Gene Therapy Scientist (Flow Cytometry)
Malvern, PA, USA
Full-time
Onsite
Entry, Mid Level
2+ years expEurofins Scientific is an international life sciences company providing analytical testing services across multiple industries. They are seeking a Cell and Gene Therapy Scientist to perform mammalian cell culture, develop methods, and maintain GMP compliant records in a dynamic laboratory environment.
BiotechnologyGeneticsHealth CareLife SciencePharmaceutical
No H1B
Responsibilities
Perform mammalian cell culture passaging/ splitting, continuous maintenance, & cell counting
Use micro pipettes for precise readings in cell-based assays like flow cytometry & plate-based assays (ELISA, Alphalisa)
Maintain electronic lab notebooks & GMP complaint record keeping
Work on new method development as well as optimize existing methods
Successful candidates are adaptable/flexible to dynamic method development settings, to accommodate quick changes in protocols
Qualification
Required
Masters degree in a scientific concentration with 2-4 years of industry experience
Ability to work with both spectral and conventional Flow assays, designing multi-color flow cytometry
GMP Industry experience on BD Lyric instrumentation, ability to troubleshoot instrumentation
Method development on BD Lyric needed
Experience with aseptic mammalian cell culture
Authorization to work in the United States indefinitely without restrictions or sponsorship
Preferred
Quick learner, be able to work independently with project guidance from client
Proactive communication skills to report daily progress/road blocks of project
Technical writing experience preferred
Self-starter, high level of integrity and accountability
Benefits
Comprehensive medical coverage
Dental
Vision options
Life and disability insurance
401(k) with company match
Paid vacation and holidays
Company
Eurofins
Eurofins provides testing and support services to the pharmaceutical, food, environmental, and consumer products industries.
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$1.05B2025-06-26Post Ipo Debt· $586.37M
2025-03-27Post Ipo Debt· $431.4M
2021-10-22Grant· $30M
Leadership Team
C
Cara Ahern
Documentation Specialist
Yves-Loic Martin
Board Member
Recent News
2025-12-16
Business Wire
2025-12-08
Company data provided by crunchbase